Latest Combination drugs Stories

Orexigen Therapeutics to Present at the UBS Global Healthcare Conference

2013-05-17 16:24:37

SAN DIEGO, May 17, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the UBS Global Healthcare Conference in New York. The presentation is scheduled for Wednesday, May 22(nd) at 11 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the...

Assessing Your Asthma is Key to Taking Control

2013-05-13 16:27:10

WILMINGTON, Del., May 13, 2013 /PRNewswire/ -- Approximately 25 million Americans suffer from asthma, which accounts for more than 3300 deaths each year. AstraZeneca (NYSE: AZN) is urging Americans to embrace National Asthma & Allergy Awareness Month this May by taking proactive steps to gain control of their asthma and learn more about how it may be impacting their lives. To view the multimedia assets associated with this release, please click:...

Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

2013-05-10 16:24:38

SAN DIEGO, May 10, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas. The presentation is scheduled for Wednesday, May 15(th) at 1 p.m. Pacific Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available...

Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013

2013-05-08 16:27:43

SAN DIEGO, May 8, 2013 /PRNewswire/ -- Orexigen(®) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter ended March 31, 2013. For the three months ended March 31, 2013, Orexigen reported a net loss of $19.4 million, or $0.21 per share, as compared to a net loss of $10.4 million, or $0.16 per share, for the first quarter of 2012. Total operating expenses for the first quarter...

Drugs.com Releases Q1 Sales for Top 100 U.S. Drugs: Rough U.S Flu Season Boosts Numbers for Tamiflu

2013-05-06 08:30:49

NEW YORK, May 6, 2013 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released first quarter 2013 U.S. prescription sales data for the top 100 drugs. (Photo: http://photos.prnewswire.com/prnh/20130506/PH07894-a )(Photo: http://photos.prnewswire.com/prnh/20130506/PH07894-b ) The top five drugs have minor shifts in rank but exhibit positive growth for Q1 2013. Abilify, Otsuka's second generation antipsychotic, and Nexium, AstraZeneca's leading acid...

Novartis Could Face Exclusion From Federal Health Care Programs If Allegations That It Carried Out Widespread Pay to Play Kickback Schemes Hold True

2013-05-02 23:02:27

U.S. government's intervention in two whistleblower lawsuits against Novartis, alleging kickbacks and other frauds, could have serious implications for the pharmaceutical giant, according to members of the Qui Tam Team. Philadelphia, PA (PRWEB) May 02, 2013 Qui Tam Team http://www.quitamteam.com; e-mail: QuiTamTeam(at)gmail(dot)com As highlighted in a piece by Jonathan Stempel of The Washington Post on April 26, 2013, following two federal lawsuits, including U.S. Attorney Preet...

Orexigen Therapeutics to Host First Quarter 2013 Financial Results Conference Call and Webcast

2013-05-02 08:38:18

SAN DIEGO, May 2, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the first quarter ended March 31, 2013, on Wednesday, May 8, 2013 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time). Orexigen management will host the call and webcast to discuss financial results and...

Orexigen Therapeutics Commends the Campaign to End Obesity's Report on Long-term Returns of Obesity Prevention Policies

2013-04-25 16:31:05

SAN DIEGO, April 25, 2013 /PRNewswire/ -- Regarding the report "The Long Term Returns of Obesity Prevention Policies" unveiled this week by the Campaign to End Obesity (CEO), Orexigen Therapeutics, Inc. (Nasdaq: OREX) issued the following statement: Orexigen commends CEO as well as the author of the report, Alex Brill, and the Robert Wood Johnson Foundation (RWJF) who funded the report, for this new research illustrating the importance of long-term budget impact analyses on...

Novartis signs on to support Malaria No More's Power of One campaign to stride towards a future without malaria

2013-04-25 12:27:39

-- Power of One donation campaign harnesses the latest web and mobile technology to rally the global public to fight malaria BASEL, Switzerland, April 25, 2013 /PRNewswire/ -- Novartis and Malaria No More, a leading global charity determined to end malaria deaths, announced today that they are joining forces on the Power of One campaign to help close the treatment gap and accelerate progress in the fight against malaria. Over the next three years, Novartis will support the...

Nuvo Research announces European launch of Pliaglis(R) by Galderma

2013-04-23 08:33:26

MISSISSAUGA, ON, April 23, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology. Marketing licenses have been...